Factor | Number of patients | Median survival time in days | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|---|---|
95%-CI in days | p-value (unadjusted, log-rank) | p-value (adjusted, cox-regression) | Hazard ratio | |||
Sex | 0.013 | 0.042 | 1.31 | |||
• Male | 159 | 235 | 172 – 298 | |||
• Female | 181 | 327 | 274 – 380 | |||
• Overall | 340 | 282 | 232 – 332 | |||
WBRT | 0.049 | ns (0.067) | 1.28 | |||
• No | 189 | 231 | 172 – 290 | |||
• Yes | 151 | 341 | 280 – 402 | |||
• Overall | 340 | 282 | 232 – 332 | |||
KPS | < 0.001 | < 0.001 | 2.19 | |||
• ≤ 70 | 82 | 122 | 84 – 160 | |||
• > 70 | 258 | 342 | 298 – 386 | |||
• Overall | 340 | 282 | 232 – 332 | |||
Histology | ns (0.488) | |||||
• NSCLC | 160 | 275 | 218 – 332 | |||
• SCLC | 27 | 231 | 151 – 331 | |||
• Melanoma | 49 | 286 | 201 – 371 | |||
• Breast Ca | 41 | 383 | 153 – 613 | |||
• RCC | 20 | 184 | 0 – 435 | |||
• Others | 43 | 265 | 36 – 582 | |||
• Overall | 340 | 282 | 217 – 494 | |||
Age | ns (0.1) | |||||
• < 65 y | 208 | 306 | 254 – 358 | |||
• ≥ 65 y | 132 | 247 | 177 – 317 | |||
• Overall | 340 | 282 | 232 – 332 | |||
Number of metastases | ns (0.764) | |||||
• 1 | 197 | 268 | 203 – 333 | |||
• 2 | 101 | 275 | 183 – 367 | |||
• 3 | 31 | 332 | 0 – 710 | |||
• 4 | 8 | 467 | 47 – 905 | |||
• 5 | 2 | 341 | – | |||
• 7 | 1 | 834 | – | |||
• Overall | 340 | 282 | 232 – 332 | |||
Dose | < 0.001 | ns | ||||
• ≤ 18 Gy | 175 | 235 | 156 – 314 | |||
• > 18 Gy | 165 | 351 | 255 – 447 | |||
340 | 282 | 232 – 332 | ||||
Volume | 0.002 | ns | ||||
• ≤ 2.5 ml | 172 | 354 | 262 – 446 | |||
• > 2.5 ml | 168 | 234 | 162 – 306 | |||
• Overall | 340 | 282 | 232 – 332 | |||
RPA class | < 0.001 | |||||
• I | 26 | 1800 | 362 – 3238 | < 0.001 | ||
• II | 271 | 281 | 227 – 335 | < 0.001 | 3.61 | |
• III | 43 | 130 | 17 – 243 | 0.001 | 3.85 | |
• Overall | 340 | 282 |